Annals of Medical & Surgical Case Reports

ISSN 2652-4414

Case Report

A Patient with Sickle Cell Disease and Beta-Mannosidosis-A Case Report

Almadani H, Namnqani R*and Kurdi H

Consultant of pediatric hematology-oncology Department of pediatrics, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia,

*Corresponding author: Dr. Housam Almadani , Consultant of pediatric hematology-oncology Department of pediatrics, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia, Tel: +966 50 468 5495; Email: dr_housam_almadani@hotmail.com

Citation: Almadani H, Namnqani R, Kurdi H (2020) A Patient with Sickle Cell Disease and Beta-Mannosidosis-A Case Report. Ann Med &Surg Case Rep: AMSCR-100061

Received date: 11 May, 2020; Accepted date: 06 June, 2020; Published date: 15 June, 2020

 

Abstract

Sickle Cell Disease (SCD) is one of the global health problems, with estimates of approximately 300,000 new cases per year di- agnosed with SCD worldwide. It is defined as a homozygous status of the sickle hemoglobin (HbS) gene which results in substitution of the amino acid valine to glutamic acid at the 6th position of the B-globin chain. B-mannosidosis is a rare glycoprotein lysosomal storage disease inherited as an autosomal recessive pattern caused by a deficient activity of beta manosidase enzyme. We report here an Eight years old male patient diagnosed with Sickle Cell Disease and Beta-mannosidosis, to our knowledge this is the first case to report a patient with SCD and B-mannosidosis.


Keyword: Acute Chest Syndrome; Beta mannosidosis; Hypersplenism; Sickle Cell Disease; Splenic Sequestration

 

Introduction

Sickle Cell Disease (SCD) is one of the global health problems, with estimates of approximately 300,000 new cases per year diagnosed with SCD worldwide. It is defined as a homozygous status of the sickle hemoglobin (HbS) gene which results in substitution of the amino acid valine to glutamic acid at the 6th position of the B-globin chain [1,2]. B-mannosidosis is a rare glycoprotein lysosomal storage disease inherited as an autosomal recessive manner caused by a deficient activity of beta manosidase enzyme [3].Acute Chest Syndrome (ACS)  is the leading cause  of death in SCD patient and the 2nd most common complication  of Sickle Cell Disease, after vaso-occlusive crisis[4]. Ssplenic sequestration and hypersplenism is a known complication as well of SCD [5]. we report a case of SCD with B-mannosidosis who  is having a recurrent ACS and hypersplenism with acute splenic sequestration.

Case report

An 8 years old boy, a product of a full term, Spontaneous Vaginal Delivery (SVD), the second childtoaconsanguineousparent. The patient presented at age of 4 months with pallor and shortness of breath with a complete blood count hemoglobin level of 7.8 mg/ dl with a sickle cell screen positive, and diagnosed as a sickle cell disease based on hemoglobin electrophoresis (HbS: 34.7% and HbF: 63.7%with no detectable HbA) which was repeated at age of one year and confirmed the diagnosis of SCD with alpha-Thalassemia trait, X-ray chest showed cardiomegaly and Echo was done and results were as dilated left ventricle and atrium with moderate mitral regurgitation and the left ventricle function of FS 17.2% and labelled as having cardiomyopathy. At age of 3 years the patient had global developmental delay, growth parameters were below 3rd centile for height and weight, he had hepatosplenomegaly, speech retardation with hearing loss and recurrent otitis media requiring later bilateral myringotomy, T tube insertion and a hearing aid. He had coarse facial features (gargoyle-like features) as frontal bossing, flat nasal bridge, large tongue with thick lips and gapped teeth, gibbus malformation with skeletal deformities (Figure 1-4) (Table 1, 2).

At 4 years of age he was diagnosed as Bronchial Asthma, Allergic Rhinitis, myopic astigmatism and Attention Deficit Hyperactive Disease (ADHD) with a lower IQ of 70 at age of 7 years.He underwent splenectomy at age of 5 years.The patient was investigated for a lysosomal storage disorder, urine Glycosamino glycan (GAG) was negative for the patient, normal blood Tandem mass spectrometry, and chromosomal analysis of 46, XY.

Whole ExomeSequence (WES) detected a homozygous variant of exon 6 of the MANBA gene mutation C.704T>G (p.lle235Arg) and both parents are with a heterozygous status. Enzymatic assay of manosidase activity in serum (Table 1).

He has a sister who had the same presentation of coarse facial features, hepatosplenomegaly, and gibbus malformation with sickle cell Trait and Beta-mannosidosis confirmed by genetic whole exome sequencing (homozygous status of MANBA gene mutation) C.704T>G) and enzyme assay (Figure5).

Discussion

Beta-mannosidosis is a pan-ethnic disorder with an autosomal recessive inheritance [6]. Two siblings from Saudi Arabia, described in our report, was associated with gargoyle like facial dysmorphism, hearing impairment, mental retardation, and recurrent respiratory tract infections.To our knowledge the number of patients reported in the literature is small, (Table 2) so, it is difficult to conclude specific symptoms and signs to characterize B-mannosidosis.Various degrees of developmental delay, hearing loss, and mental retardation are common findings. The older sibling has angiokeratoma as an isolated observation as reported previously[21,22]. The observed skeletal changes in our proband are beaked vertebral bodies, thick calvarium, bullet shaped vertebrae, and gibbus malformation (Figure.2).

This patient who is a known case of hypersplenism with multiple splenic sequestration with one intensive care admission with critical hemoglobin level 3.4 mg/dl. Post elective splenectomy the patient had significant decreased rate of admission and blood transfusions. It was noticed that in our proband who has beta- mannosidosis the most frequent complication of sickle cell disease is hypersplenism with sequestration and acute chest syndrome with fewer painful crisis’s although it is the most common feature of sickle cell disease[23]. The patient had frequent admissions as an acute chest syndrome in which after starting azithromycin as an anti-inflammatory agent[24,25] by our pulmonologist, the rate of acute chest syndrome related admission decreased.

The association of Beta mannosidosis and SCD to our knowledge has not been reported before, this combination of both diseases need further reported cases to establish the impact.

Conclusion

This is the first case to report a patient with SCD and B-mannosidosis. We recommend splenectomy for  cases  of Sickle Cell Disease with B-mannosidosis and  hypersplenism,  we recommend using azithromycin as an anti-inflammatory prophylactic agent to reduce Acute Chest Syndrome in patient with Sickle Cell Disease andBeta mannosidosis.


Figures

Figure 1:X-ray skull showing calvarial thickening and bullet shaped vertebrae.

Figure 2:X-ray of right upper limb showing expansion of medullary spaces with short tubular bones of the hand.

Figure 3: X-ray lateral spine showing L2 vertebral breaking with gibbus malformation.

Figure 4: CT Abdomen showing anterior inferior beaking of L2 vertebrae with gibbus malformation.

Figure 5: Family pedigree


 

Source

enzyme

Activity

Reference range

Serum

Beta-mannosidase

0.004 umol/ml/min

1.49- 8.33 umol/ml/min

Serum

Alpha-mannosidase

0.14 umol/ml/min

0.1 -0.2 umol/ml/min

Table1: Enzymatic assay of Mannosidase enzyme activity in our proband.

 

TABLE 2. Beta-mannosidosis phenotype and laboratory findings in reported cases

Case

1

2

3

4

5

6

7

8

9

10

11

Sex

Male

Male

Male

Male

Male

Female

Male

Female

Female

Male

Male

Ethnicity

European

Hindu

Hindu

Turkish

Turkish

Czech

Czech

Jamaican

Turkish

European

African

Consanguinity

Negative

 

 

Positive

positive

 

 

Negative

positive

Negative

Negative

Diagnosis age (Yr)

1.5

44

19

8

6

20

30

1

6

3

14

Presenting symptom

Dysmorphology

Mental retardation

 

Feeding difficulty

 

Developmental delay

 

Seizures

Absent speech

Speech impairment

Speech impairment

Mental retardation

Positive

Positive

Yes

Yes

Yes

Positive

Positive

 

Positive

Positive

Negative

Behavioral problems

Hyperactive

aggressive

 

Troublesome

 

Aggressive

 

 

Hyperactive aggressive

Hyperactive

Disinterest

Hearing impairment

Mild

Present

Present

Present

Present

Present

Present

Negative

Present

Negative

Negative

Neurological

Speech retard

 

 

Speech retard

 

Developmental delay

 

Developmental delay

Motor delay

Speech impairment

Peripheral neuropathy

dermatologic

 

Angiokeratoma

 

 

 

Erysipelas

 

 

 

 

 

Facial dysmorphism

Present

negative

Negative

Negative

Negative

Present

Present

Present

Present

Present

Negative

Skeletal deformation

Present

Negative

Negative

Negative

Negative

Present

Present

Negative

Present

Negative

Negative

Respiratory infections

 

 

 

Positive

positive

Positive

Positive

 

Positive

Positive

Negative

mannosidase

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Urine disaccharides

Positive

Positive

Positive

Positive

positive

Positive

Positive

Positive

Positive

Positive

Faint

Reference

Wenger et al. 1986[7]

Cooper et al. 1986-1988[21,22]]

Cooper et al. 1986-1988[21,22]

Dorland et al. 1988[8]

Dorland et al. 1988[8]

Kleijer et al. 1990[6]

Kleijer et al. 1990[6]

Cooper et al. 1991[9]

Wijburg et al. 1992[10]

Poenaru et al. 1992[11]

Levade et al. 1994[3]

 

Cont. TABLE 2. Beta-mannosidosis phenotype and laboratory findings in reported cases (To our knowledge)

Sibling sister

our case

Case

12

13

14

15

16

17

18

19

20

21

22

23

Sex

Female

Female

Female

Female

Male

Male

Female

Female

Male

Female

female

Male

Ethnicity

white

 

Arabic

Arabic

Japanese

French

Spanish

Arabic

Algerian

Asian

Arabic

Arabic

Consanguinity

Negative

Positive

Positive

positive

Positive

negative

 

Positive

Positive

Positive

positive

Positive

Diagnosis age

22 years

7 months

2 years

3.5 years

51 years

18 years

24 years

36 years

12 years

5 months

7 years

5 years

Presenting symptom

clumsiness

Feeding difficulty

Seizures

Seizures

Angiokeratoma

Developmental delay

Angiokeratoma

Angiokeratoma

Clumsiness

Seizures

Dysmorphism

Dysmorphism

Mental retardation

Negative

 

Positive

positive

Positive

Positive

Negative

Positive

Positive

Positive

Positive

Positive

Behavioral problems

Scantly communicative

 

 

 

 

ADHD

Negative

Aggressive

 

 

ADHD

ADHD

Hearing impairment

Negative

 

Negative

negative

Present

Present

Mild

Present

Present

Present

Present

Present

Neurological

Negative

Developmental delay

Developmental delay, speech delay

encephalopathy

Peripheral neuropathy

Developmental delay, speech delay

Negative

 

Cerebellar ataxia

Developmental delay

Developmental delay

Developmental delay

dermatologic

Angiokeratoma

 

Negative

Negative

Angiokeratoma

Negative

Angiokeratoma

Angiokeratoma

Negative

 

Angiokeratoma

Negative

Facial dysmorphism

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Positive

Positive

Positive

Skeletal deformation

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Negative

Positive

Positive

Positive

Respiratory infections

Negative

positive

Negative

Negative

 

Positive

 

Negative

 

Positive

Positive

Positive

mannosidase

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Deficient

Urine disaccharide

Positive

Positive

 

 

 

Positive

Positive

 

 

 

Positive

Positive

Reference

Rodriguez et al. 1996[12]

Gourrier et al. 1997[13]

Cherian et al. 2003[14]

Cherian et al. 2003[14]

Suzuki et al. 2004[15]

Sedel et al. 2006 [16]

Gort et al. 2006 [17]

Molho et al. 2007 [18]

 Levade et al. 2009[19]

Broomfield et al. 2012[20]

Almadani et al 2019

Almadani et al. 2019


  1. Farrell K, Dent L, Nguyen ML, Buchowski M, Bhatt A, AguinagaMdelP (2010) The relationship of oxygen transport and cardiac index for the prevention of sickle cell crises. J Natl Med Assoc 102:1000-1007.
  2. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN (2013) Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med 10:e1001484.
  3. Levade T, Graber D, Flurin V, Delisle MB, Pieraggi MT, et al. (1994) Human b-mannosidase deficiency associated with peripheral neuropathy. Ann. Neurol 35: 116–119.
  4. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, et al. (2000) Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 342:1855-1865.
  5. Topley JM, Rogers DW, Stevens MC (1981) Acute splenic sequestration and hypersplenism in the first five years in homozygous sickle cell disease. Arch Dis Child56:765-769.
  6. Kleijer WJ, Hu P, Thoomes R, Boer M, Huijmans JGM, et al. (1990) Mannosidase deficiency: heterogeneous manifestations in the first female patient and her brother, J. Inherit. Metab. Dis 13: 867-872.
  7. Wenger DA, Sujansky E, Fennessey PV, Thompson JN (1986) Human b-mannosidase deficiency. N. Engl. J. Med. 315: 1201-1205.
  8. Dorland L, Duran M, Hoefnagels FET, Breg JN, Fabery de Jonge H, et al. (1988) Beta-mannosidosis in two brothers with hearing loss, J. Inherit. Metab. Dis 11: 255-258.
  9. Cooper A, Wraith JE, Savage WJ, Thornley M, Noronha MJ (1991) Beta-mannosidase deficiency in a female infant with epileptic encephalopathy, J. Inherit. Metab. Dis 14: 18-22.
  10. Wijburg H, De Jong J, Wevers R, Bakkeren J, Trijbels F, Sengers R (1992) Beta-mannosidosis and ethanolaminuria in a female patient, Eur. J. Pediatr 151: 311.
  11. Poenaru L, Akli S, Rocchiccioli F, Eydoux P, Zamet P (1992) Human b-mannosidosis: A 3-year-old boy with speech impairment and emotional instability, Clin. Genet 41: 331-334.
  12. Rodriguez-Serna M, Botella-Estrada R, Chabas A, Coll MJ, Oliver V, et al. (1996) AngiokeratomaCorporisDiffusum associated with b-mannosidase deficiency. Arch. Dermatol 132: 1219-1222.
  13. Gourrier E, Thomas MP, Munnich A, Poenaru L, Asensi D, et al. (1997) Beta- mannosidosis: A new case of, Arch. Pediatr 4: 147-151.
  14. Cherian MP (2004) β-Mannosidase Deficiency in Two Mentally Retarded Girls with Intractable Seizures. Ann Saudi Med 24: 393-395.
  15. SuzukiN, Konohana I,FukushigeT, Tamotsu K (2004) Mannosidosis with AngiokeratomaCorporisDiffusum. The Journal of dermatology 31: 931-935.
  16. Sedel F, Friderici K, Nummy K, Cailaud C, Chabli A, et al. (2006) Atypical Gilles de la Tourette Syndrome with β-Mannosidase Deficiency. Arch Neurol 63: 129-131.
  17. Laura G, Joana D,Fabeiro JM, Zulaica A,CollMJ, et al. (2006) Molecular analysis in two Beta-mannosidosis patients: Description of a new adult case. Molecular genetics and metabolism 89: 398-400.
  18. Molho-Pessach V, Bargal R, Abramowitz Y, Victoria D, Ingber A, et al. (2007) Angiokeratomacorporisdiffusum in human Beta-mannosidosis: Report of a new case and a novel mutation. Journal of the American Academy of Dermatology 57: 407-412.
  19. Labauge P, Renard D, Castelnovo G, Sabourdy F,Levade, T, et al. (2008) Beta-mannosidosis: A new cause of spinocerebellar ataxia. Clinical neurology and neurosurgery 111: 109-110.
  20. Broomfield A, Gunny R, Ali I,Vellodi A, Prabhakar P (2013) A Clinically Severe Variant of β-Mannosidosis, Presenting with Neonatal Onset Epilepsy with Subsequent Evolution of Hydrocephalus. JIMD reports 11: 93-97.
  21. Cooper A, Sardharwalla IB, Roberts MM(1986) Human b-mannosidase deficiency. N. Engl. J. Med 315: 1231.
  22. Cooper A, Hatton C, Thornley M, Sardharwalla IB (1988) Human Beta-mannosidase deficiency: Biochemical findings in plasma, fibroblasts, white cells and urine. J. Inher. Metab. Dis 1: 17-29.
  23. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA (2010) Acute care utilization and rehospitalizations for sickle cell disease. JAMA 303:1288-1294.
  24. Culic O, Erakovic V, CepelakI, Barisic K, Brajsa K, etal. (2002) Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol450:277-289.
  25. PeneDumitrescu T, Anic-Milic T, Oreskovic K, Padovan J, Bruowar KLR, et al. (2013) Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. Antimicrob. Agents Chemother57: 3194-3201.

Citation: Almadani H, Namnqani R, Kurdi H (2020) A Patient with Sickle Cell Disease and Beta-Mannosidosis-A Case Report. Ann Med &Surg Case Rep: AMSCR-100061